An estimated 14 million cancer cases occurred world-wide during 2012 which is expected to increase to about 24 million by 2035.   While having a wide diversity of cancer types and characterizations, all cancer types involve several hallmarks include sustaining proliferative signaling, evading growth suppressors and resisting cell death. NIBN's cancer research group focuses on multi-disciplinary themes include understanding cancer biology through epigenetic modifications (eg. DNA and protein methylation changes), metabolic re-programing,  the role of dysregulated cell growth, evading apoptotic cell death and mitochondrial involvement (via voltage-dependent anion channels), the development of appropriate immune-stimulatory strategies by targeting Proliferating Cell Nuclear Antigen (PCNA), the development of innovative animal models to simulate human leukaemias and solid cancers, development of innovative diagnostic tools and the rationale design of small molecules,  siRNA's, peptides and protein-based anti-cancer therapeutics including bispecific molecules.


Group members